Novalis Biotechnology Incubation

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Alithea Genomics is a Switzerland-based company specializing in RNA sequencing and transcriptomics. Leveraging its expertise in bioengineering, molecular biology, and genomics, the company has developed proprietary technology aimed at enhancing the efficiency of Ribonucleic acid sequencing. This technology not only reduces operational costs but also significantly increases the throughput of analyzed samples. As a result, Alithea Genomics provides pharmaceutical companies with the tools necessary for advanced biomedical research and discoveries, enabling them to accelerate their development processes and improve research outcomes.

Altavo is a medical device company that leverages machine learning and advanced sensor technology to enhance the lives of individuals who have lost their voice. It specializes in creating custom, natural-sounding artificial voices for people with speech disorders, enabling them to communicate more effectively.

Rarity Bioscience is a biotechnology company that specializes in developing advanced molecular amplification technology for the detection of nucleic acid sequences. The company’s primary focus is on creating ultrasensitive multiplex assays capable of identifying small amounts of DNA sequence variants in biological samples, particularly in liquid biopsies. This innovative platform provides valuable tools for both research and clinical applications, enhancing the ability of physicians to detect rare genetic variations that may be critical for diagnosis and treatment. Through its technology, Rarity Bioscience aims to improve the precision and effectiveness of molecular diagnostics.

C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care through point-of-care solutions. The company specializes in ambulant diagnostic devices that facilitate blood coagulation testing, allowing patients to perform up to twelve different reactions using a small volume of blood. This technology is designed to empower patients to conduct tests in various settings, including at home, while traveling, or in critical care environments, all without the need for traditional laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve quality of life while maintaining cost-effectiveness in healthcare.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Carroucell is a supplier of microcarriers specifically designed for cell culture in bioreactors. The company has developed a unique platform featuring flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing by addressing common challenges associated with cell culture performance. Through its specialized products, Carroucell supports advancements in the field of cell culture, contributing to the overall improvement of biotechnological processes.

Alithea Genomics is a Switzerland-based company specializing in RNA sequencing and transcriptomics. Leveraging its expertise in bioengineering, molecular biology, and genomics, the company has developed proprietary technology aimed at enhancing the efficiency of Ribonucleic acid sequencing. This technology not only reduces operational costs but also significantly increases the throughput of analyzed samples. As a result, Alithea Genomics provides pharmaceutical companies with the tools necessary for advanced biomedical research and discoveries, enabling them to accelerate their development processes and improve research outcomes.

Trince is a biotechnology company focused on advancing cell-based science and therapeutics through innovative cell transfection technology. The company specializes in the delivery of molecules into cells both in vitro and ex vivo, utilizing a platform that integrates laser exposure with photothermal nanoparticles. This technology converts light energy into heat, allowing for the transient permeabilization of the cellular plasma membrane. As a result, Trince enables clients to introduce genetic material into cells efficiently and at high throughput, thereby enhancing research and therapeutic applications in the life sciences sector.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products. Its platform combines all lyophilization steps into a single continuous production line with constant infeed and outfeed, addressing scale-up challenges and reducing cycle times. The approach enables faster formulation development, shorter time-to-market, and lower production costs, while supporting smaller manufacturing installations and reduced cleanroom space. The system promises enhanced quality assurance with potential for real-time release and aims to deliver consistent product quality and process uniformity across batches. The technology encompasses advanced lyophilization processes and GMP-compliant systems designed to overcome limitations of traditional batch freeze-drying and accelerate development timelines.

Grapheal is a Medtech startup specializing in embedded and wearable biosensors. Utilizing graphene transistors, their wireless sensors enable accurate field diagnostics and remote patient monitoring for various biomarkers and pathogens.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care through point-of-care solutions. The company specializes in ambulant diagnostic devices that facilitate blood coagulation testing, allowing patients to perform up to twelve different reactions using a small volume of blood. This technology is designed to empower patients to conduct tests in various settings, including at home, while traveling, or in critical care environments, all without the need for traditional laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve quality of life while maintaining cost-effectiveness in healthcare.